Literature DB >> 21707491

Regulation of sphingosine kinase in hematological malignancies and other cancers.

Stuart M Pitson1, Jason A Powell, Claudine S Bonder.   

Abstract

The sphingolipids ceramide, sphingosine and sphingosine 1-phosphate have emerged as important signaling molecules that regulate a number of important cellular processes. Sphingosine 1-phosphate enhances cell survival and proliferation, and also regulates angiogenesis, cell invasion, and differentiation via both its cell surface G protein-coupled receptors and recently identified intracellular effectors. In contrast, ceramide and sphingosine elicit growth arrest and apoptosis through direct modulation of a number of intracellular targets. The cellular balance of these sphingolipids contributes to the determination of cell fate, and it is now clear that disruption in this 'sphingolipid rheostat' contributes to the development, progression and chemotherapeutic resistance of both hematological malignancies and solid tumors. The sphingosine kinases are central regulators of this pathway since they not only increase sphingosine 1-phosphate and assist in reduction of ceramide and sphingosine, but are also regulated at multiple levels by external stimuli. Thus, targeting the regulation of the sphingosine kinases may be a viable therapeutic strategy for a diverse array of cancers. Here, we describe the current knowledge of sphingosine kinase regulation, effects of current and potential chemotherapeutic agents on this system, and discuss the implications of this for the treatment of hematological malignancies and other cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707491     DOI: 10.2174/187152011797655078

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  14 in total

1.  Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.

Authors:  Hoe-Sup Byun; Susan Pyne; Neil Macritchie; Nigel J Pyne; Robert Bittman
Journal:  Medchemcomm       Date:  2013       Impact factor: 3.597

2.  The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.

Authors:  Taryn E Dick; Jeremy A Hengst; Todd E Fox; Ashley L Colledge; Vijay P Kale; Shen-Shu Sung; Arun Sharma; Shantu Amin; Thomas P Loughran; Mark Kester; Hong-Gang Wang; Jong K Yun
Journal:  J Pharmacol Exp Ther       Date:  2015-01-06       Impact factor: 4.030

3.  Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma.

Authors:  Yunze Xu; Baijun Dong; Jianfeng Wang; Jin Zhang; Wei Xue; Yiran Huang
Journal:  Oncoimmunology       Date:  2018-09-25       Impact factor: 8.110

4.  A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.

Authors:  Mohamed F Salama; Brittany Carroll; Mohamad Adada; Michael Pulkoski-Gross; Yusuf A Hannun; Lina M Obeid
Journal:  FASEB J       Date:  2015-03-24       Impact factor: 5.191

5.  SPHK1 inhibitor suppresses cell proliferation and invasion associated with the inhibition of NF-κB pathway in hepatocellular carcinoma.

Authors:  Zijie Zhang; Zhenyu Yan; Zheng Yuan; Yanzhen Sun; Haifa He; Chunyang Mai
Journal:  Tumour Biol       Date:  2014-12-24

6.  Sphingosine Kinase Regulates Neuropeptide Secretion During the Oxidative Stress-Response Through Intertissue Signaling.

Authors:  Sungjin Kim; Derek Sieburth
Journal:  J Neurosci       Date:  2018-08-06       Impact factor: 6.167

7.  Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.

Authors:  Jason A Powell; Alexander C Lewis; Wenying Zhu; John Toubia; Melissa R Pitman; Craig T Wallington-Beddoe; Paul A B Moretti; Diana Iarossi; Saumya E Samaraweera; Nik Cummings; Hayley S Ramshaw; Daniel Thomas; Andrew H Wei; Angel F Lopez; Richard J D'Andrea; Ian D Lewis; Stuart M Pitson
Journal:  Blood       Date:  2016-12-12       Impact factor: 22.113

8.  Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.

Authors:  Craig T Wallington-Beddoe; Melissa K Bennett; Kate Vandyke; Lorena Davies; Julia R Zebol; Paul A B Moretti; Melissa R Pitman; Duncan R Hewett; Andrew C W Zannettino; Stuart M Pitson
Journal:  Oncotarget       Date:  2017-07-04

9.  Sphingolipids: a potential molecular approach to treat allergic inflammation.

Authors:  Wai Y Sun; Claudine S Bonder
Journal:  J Allergy (Cairo)       Date:  2012-12-18

Review 10.  Emerging role of sphingosine-1-phosphate signaling in head and neck squamous cell carcinoma.

Authors:  Rajeev Nema; Supriya Vishwakarma; Rahul Agarwal; Rajendra Kumar Panday; Ashok Kumar
Journal:  Onco Targets Ther       Date:  2016-05-31       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.